###begin article-title 0
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
Disturbances in peripheral blood memory B cell subpopulations have been observed in various autoimmune diseases, but have not been fully delineated in rheumatoid arthritis (RA). Additionally, the possible role of tumour necrosis factor (TNF) in regulating changes in specific peripheral blood memory B cell subsets in RA is still unclear.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
The frequency and distribution of B cell subsets in the peripheral blood and synovial membrane of active RA patients with long-standing disease have been analysed. Additionally, the possible role of TNF in causing disturbances in memory B cell subsets in RA patients was assessed in a clinical trial with the specific TNF-neutralising antibody, infliximab.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 122 124 122 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 188 189 188 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 193 195 193 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 267 268 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 272 274 272 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 293 294 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 298 300 298 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 434 435 434 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
RA patients, independent of disease duration, have a significantly lower frequency of peripheral blood pre-switch IgD+CD27+ memory B cells than healthy individuals, whereas post-switch IgD-CD27+ accumulate with increased disease duration. Notably, both pre-switch IgD+CD27+ and post-switch IgD-CD27+ memory B cells accumulate in the synovial membrane of RA patients. Finally, anti-TNF therapy increased the frequency of pre-switch IgD+CD27 memory B cells in the peripheral blood.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
The data suggest that decreases in peripheral blood IgD+CD27+ pre-switch memory B cells in RA reflect their accumulation in the synovial tissue. Moreover, the significant increase in the peripheral blood pre-switch memory B cells in patients who underwent specific TNF-blockade with infliximab indicates that trafficking of memory B cells into inflamed tissue in RA patients is regulated by TNF and can be corrected by neutralising TNF.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 253 254 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease, characterised by inflammatory polyarthritis and joint damage resulting in progressive disability [1]. The inflammatory infiltrate in RA includes T cells, B cells and dendritic cells [2-4], and in approximately 20% of patients lymphoid neogenesis develops with the formation of ectopic germinal centres [5-8].
###end p 11
###begin p 12
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
The importance of B cells in RA has been emphasised by the success of therapeutic approaches using anti-CD20 monoclonal antibodies (mAbs) [9]. It is currently unknown whether this approach to treatment is successful because of the production of early plasma cells due to the loss of rheumatoid factor or because of other functions of B cells.
###end p 12
###begin p 13
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 165 166 165 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 199 200 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 204 206 204 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 368 370 368 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 880 882 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
Functionally distinct B cell subsets can be defined by the surface expression of immunoglobulin (Ig) D and CD27. These include naive IgD+CD27-; pre-switch memory IgD+CD27+; and post-switch memory IgD-CD27+ [10-12]. Importantly, CD27 expression by B cells has been considered a hallmark for cells that have undergone somatic hypermutation [13], although recently a CD27- population of memory B cells with mutated Ig genes has been described [14-16], which is elevated in patients with systemic lupus erythematosus (SLE) [15]. Abnormalities in the frequencies of peripheral blood memory B cells have been reported in SLE [17], and Sjogren's syndrome (SS) [18]. However, in RA the data on possible disturbances of peripheral blood B cell distributions have not been delineated as well. Part of this could relate to differences in disease duration and therapy of the cohorts studied [19-21].
###end p 13
###begin p 14
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 516 517 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 546 548 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1258 1260 1242 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1317 1319 1301 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
Treatment with TNF blockers ameliorates the signs and symptoms of RA and disease progression [22-25]. Recently, a study of peripheral blood and tonsilar biopsies from RA patients undergoing treatment with the combined TNF and lymphotoxin alpha (LTalpha) antagonist, etanercept, suggested that part of the success of this therapy in RA could be linked to a disruption of follicular dendritic cell (FDC) networks in secondary lymphoid organs, thus impairing germinal centre formation, and decreasing the number of CD27+memory B cells in the blood [19]. However, this effect was noted in the tonsil, making it uncertain whether etanercept would have a similar impact on germinal centres in the spleen and lymph nodes. Etanercept neutralises both TNF and LTalpha, so it is difficult to determine the possible contribution of each cytokine to the effects noted. TNF and LTalpha have many non-overlapping functions and, therefore, distinct effects of blocking each of these two cytokines on memory B cell homeostasis are possible. For example, TNF is involved in the regulation of the expression of adhesion molecules, such as vascular cell adhesion molecule (VCAM-1), intercellular adhesion molecule (ICAM-1), P-selectin, E-selectin, and L-selectin (reviewed in [26]) and also vascular endothelial growth factor (VEGF)-C [27], suggesting that it may play a crucial role in the neovascularisation of rheumatoid synovium and also recruitment of lymphocytes into the inflamed synovium.
###end p 14
###begin p 15
###xml 641 642 641 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 646 648 646 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 712 713 712 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 717 719 717 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 831 832 831 832 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 836 838 836 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1040 1041 1040 1041 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 536 544 <span type="species:ncbi:9606">patients</span>
###xml 895 903 <span type="species:ncbi:9606">patients</span>
In order to study the changes in peripheral memory B cell subpopulations in RA patients, and to understand the possible role of TNF in regulating changes in specific memory B cells, we analysed the frequency and distribution of B cell subsets in the peripheral blood and synovial membrane of active RA patients with long-standing disease. Subsequently, we assessed whether treatment with the specific TNF-blocker, infliximab, normalised the distribution of these peripheral B cell subsets. Our results show, for the first time, that RA patients, independent of disease duration, have a much lower frequency of peripheral blood pre-switch IgD+CD27+ memory B cells than healthy individuals, whereas post-switch IgD-CD27+ memory B cells accumulate with increased disease duration. Additionally, we present evidence that pre-switch IgD+CD27+ memory B cells accumulate in the synovial membrane of RA patients, and that this accumulation might be related to the influence of TNF, because anti-TNF therapy increased the frequency of pre-switch IgD+CD27 memory B cells in the peripheral blood. These results document disease-related and TNF-dependent abnormalities in memory B cell subsets in RA and suggest that part of the success of TNF neutralising therapy could relate to normalisation of memory B cell abnormalities.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 17
###begin p 18
###xml 167 175 <span type="species:ncbi:9606">patients</span>
Peripheral blood samples from 40 healthy donors (26 females, 14 males; mean age 44 years) were obtained from the National Institutes of Health blood bank, and from 33 patients (28 females, five males; mean age 57 years) with long-standing RA (median disease length, 13 years) enrolled in a natural history protocol (00-AR-0222) at the Warren G. Magnuson Clinical Center (National Institutes of Health, Bethesda, Maryland, USA).
###end p 18
###begin p 19
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">Patients</span>
###xml 718 726 <span type="species:ncbi:9606">patients</span>
In addition, blood samples were obtained from 23 patients (20 females, 3 males; mean age 48.5 years) with active RA (defined as having greater than four tender and swollen joints, erythrocyte sedimentation rate (ESR) greater than 20 mm/hour or C-reactive protein (CRP) greater than 0.8 mg/dl) who failed treatment with methotrexate (MTX; 12.5 to 15 mg/week) and were entering a clinical trial of infliximab therapy (00-AR-0220). For this trial, patients on prednisone had to be on 7.5 mg or less per day to be eligible to participate. Patients were randomised to receive either monthly infliximab infusions (3 mg/kg infliximab with MTX 15 mg/week), or monthly control infusions and weekly MTX alone (<25 mg/week). All patients fulfilled the revised American College of Rheumatology criteria for RA [28]. MB, carrying out the flow cytometric analysis, was blinded to the measurements of clinical response and disease activity scores.
###end p 19
###begin p 20
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
The group of patients enrolled in the natural history protocol, with a median disease length of 13 years, were considered as the long-standing disease group. The group of patients enrolled in the clinical trial for infliximab, with a median disease duration of 4.4 years, were considered as the group with shorter disease duration.
###end p 20
###begin p 21
Synovial specimens and peripheral blood samples were collected at the Department of Rheumatology, Tokyo Medical and Dental University from 10 RA subjects with long-standing disease (median disease length of 13.5 years).
###end p 21
###begin p 22
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
The characteristics of all patients studied are shown in Table 1.
###end p 22
###begin p 23
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Clinical and demographic characteristics of the RA patients
###end p 23
###begin p 24
Data are means +/- standard deviation.
###end p 24
###begin p 25
CRP = C-reactive protein; DMARD = disease-modifying anti-rheumatic drug; ESR = erythrocyte sedimentation rate; GC = glucocorticoids; MTX = methotrexate; RA = rheumatoid arthritis; RF = rheumatoid factor.
###end p 25
###begin p 26
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 235 242 <span type="species:ncbi:9606">Patient</span>
The local institutional review board or the ethics committees (National Institutes of Health and Tokyo Medical and Dental University) approved the studies and all patients signed an informed consent before participating in this study. Patient's management was performed in accordance with the local standard practice and the study was conducted in accordance with the regulations governing clinical trials, such as the Declaration of Helsinki as amended in Edinburgh (2000).
###end p 26
###begin title 27
Lymphocyte phenotyping
###end title 27
###begin title 28
Peripheral Blood
###end title 28
###begin p 29
###xml 270 272 270 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 512 517 <span type="species:ncbi:9606">human</span>
Peripheral blood samples from the controls and natural history patients were obtained during a single scheduled outpatient visit. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient centrifugation and re-suspended in 1.5 ml PBS and 1% BSA (1 x 106 cells/100 muL). Isolated PBMCs were stained by standard methods with fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin-chlorophyll-protein Cy5.5 (PerCpCy5.5) or allophycocyanin (APC) conjugated mAb specific for the following human cell surface markers: anti-CD19 PerCpCy5.5, anti-CD27 PE, anti-IgD FITC and anti-IgM FITC (all mAb were obtained from BD Pharmingen, Franklin Lakes, NJ, USA). Data were acquired on a FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA).
###end p 29
###begin p 30
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Peripheral blood samples from the RA patients treated with MTX and infliximab or MTX alone were obtained before and after treatment. Anticoagulated samples were stained for three-colour flow cytometry using a whole blood staining method at the National Institutes of Health Clinical Center laboratory. B cells were identified by staining with anti-CD20 APC and anti-CD27 PE (BD Biosciences, San Jose, CA, USA) and anti-IgD FITC (Caltag, Burlingame, CA, USA). T cells were identified by anti-CD3 APC or PE, anti-CD4 PE, anti-CD8 FITC or APC, anti-CD45RA FITC and anti-CD45R0 APC (BD Biosciences, San Jose, CA, USA).
###end p 30
###begin p 31
###xml 344 352 <span type="species:ncbi:9606">patients</span>
To calculate absolute numbers of each lymphocyte subset, the percentage of cells staining positively was multiplied by the absolute peripheral blood lymphocyte count, which was determined by cell counting with a Celldyne 3500 (Abbott, Santa Clara, CA, USA) blood cell counting machine. With all experiments, peripheral blood from healthy adult patients was stained and analysed as controls.
###end p 31
###begin p 32
###xml 111 116 <span type="species:ncbi:9606">human</span>
To determine the chemokine receptor expression by B cells and their subsets, the following APC-conjugated anti-human mAbs were used: anti-CXCR1, anti CXCR2 and anti-CCR2 (R&D Systems, Minneapolis, MN, USA); and anti-CXCR4 (BD Biosciences, San Jose, CA, USA).
###end p 32
###begin p 33
###xml 342 344 342 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 351 352 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 392 394 392 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 413 414 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 418 420 418 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 432 433 432 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 437 439 437 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 466 467 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 471 473 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 623 624 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 628 630 628 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink">++</sup>
###xml 633 634 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 33 39 <span type="species:ncbi:10090">murine</span>
Irrelevant, directly conjugated, murine IgG1 (BD Biosciences, San Jose, CA, USA) was used to ascertain background staining. Samples were run on a FACScan or a FACSCalibur (BD Biosciences, San Jose, CA, USA). Data were analysed using the WinList software, version 5.0, and FloJo software (TreeStar, Stanford University, CA, USA). B cells (CD20+ or CD19+) were gated and the percentages of CD27+ (total memory), IgD+CD27- (naive), IgD+CD27+ (pre-switch memory) and IgD-CD27+ (post-switch memory) populations in the gated B cells were calculated. Although anti-CD20 mAb do not identify all plasmablasts, most of which are CD19+CD27++IgD-, the results from both staining protocols were pooled together, because no significant differences in total or post-switch memory B cells were observed when analysing the results separately.
###end p 33
###begin p 34
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 53 55 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 74 76 74 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 98 99 98 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 105 107 105 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 135 136 135 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 142 144 142 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
T cells (CD3+) were gated, and the precentages of CD4+ (total helper), CD8+ (total cytotoxic), CD4+CD45RA+ (total naive helper) and CD4+CD45R0+ (total memory helper) populations within the T cell population were calculated.
###end p 34
###begin title 35
Synovial specimens
###end title 35
###begin p 36
###xml 719 721 713 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Synovial tissues were obtained during joint replacement surgery from 10 RA patients. Specimens were minced and incubated with 0.3 mg/ml of collagenase (Sigma, St. Louis, MO, USA) for one hour at 37degreesC in Dulbecco's Modified Eagle's Medium (DMEM; Sigma, St. Louis, MO, USA). Partially digested pieces of the tissue were pressed through a metal screen to obtain single cell suspensions. Cells were stained with anti-CD19 PECy5 (Beckman Coulter, Fullerton, CA, USA), anti-CD27 FITC, anti-IgM PE and anti-IgD PE (all from Becton Dickinson, Fullerton, CA, USA), anti-CXCR1 PE, anti-CXCR2 PE, anti-CXCR4 PE and anti-CCR2 PE (all from R&D Systems Inc., Minneapolis, MN. USA). Synovial tissue cells were adjusted to 1 x 105 cells, and incubated with the above mAbs for 30 minutes, rinsed with PBS-3% FCS, and analysed with a FACSCalibur (Becton Dickinson, Fullerton, CA, USA).
###end p 36
###begin title 37
Amplification of the IgV heavy chain by single-cell PCR
###end title 37
###begin p 38
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 13 15 13 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 46 48 46 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 527 529 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 577 581 575 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 759 763 755 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 959 963 953 955 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 991 993 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
CD19+IgD+CD27- naive B cells and CD19+IgD+CD27+ memory B cells from four patients with RA were sorted using a Beckton Dickinson FACS DIVA (Fullerton, CA, USA) or a Dako Cytomation MoFlo (Dako Cytomation, Ft Collins, CO, USA) and 1 to 1.5 cells/5 muL PBS, and then plated into 96-well PCR plates containing 10 muL lysis buffer (2 x PCR buffer + 0.4 mg/ml proteinase K (Sigma, St. Louis, MO, USA)), subjected to primer extension pre-amplification and then VH3 and VH4 genes were amplified by nested PCR, as previously described [29]. PCR products were purified using the Performa(R) 96-Well Standard Plate kit (Edge BioSystems, Gaithersburg, MD, USA) and sequenced on a model 3100 capillary sequencer (Applied Biosystems, Foster City, CA, USA) using the Big Dye(R) Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). Ig variable heavy chain rearrangements were analysed for somatic mutations using the web-based algorithm JOINSOLVER(R) (NIAMS/CIT, Maryland, USA) [30].
###end p 38
###begin title 39
Soluble CD27 ELISA
###end title 39
###begin p 40
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 156 161 <span type="species:ncbi:9606">human</span>
The level of soluble CD27 was determined in serum samples from RA patients in the natural history protocol and healthy controls using the PeliKline Compact human soluble CD27 ELISA kit (CLB, Central Laboratory of the Netherlands Red Cross, Amsterdam, The Netherlands) according to the manufacturer's instructions.
###end p 40
###begin title 41
Statistical analyses
###end title 41
###begin p 42
###xml 257 265 <span type="species:ncbi:9606">patients</span>
Data were checked for a normal distribution in order to decide whether to use parametric or non-parametric tests. Median group values (with standard error of the mean) for percentage and absolute numbers of the different B cell populations were compared in patients and healthy controls using the nonparametric unpaired Mann-Whitney test.
###end p 42
###begin p 43
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Mean values (with standard deviation) of the CD27+ memory B cell population were compared between the synovium and peripheral blood of 10 RA patients undergoing synovectomy using a paired Student's t-test.
###end p 43
###begin p 44
###xml 266 268 266 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
Median group values (with standard error of the mean) of the different B cell populations compared pre- and post-treatment in the 23 RA patients who were treated with infliximab plus MTX or MTX monotherapy using the nonparametric paired Wilcoxon Signed Rank test. A P < 0.05 was considered statistically significant.
###end p 44
###begin title 45
Results
###end title 45
###begin title 46
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Characteristics of the RA patients
###end title 46
###begin p 47
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 55 62 <span type="species:ncbi:9606">patient</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 167 172 <span type="species:ncbi:9606">women</span>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
###xml 465 470 <span type="species:ncbi:9606">women</span>
The demographic and clinical characteristics of the RA patient groups evaluated in this study are shown in Table 1. Most of the 33 patients with long-standing RA were women with chronic (median disease duration of 13 years), rheumatoid factor-positive erosive disease. All patients were receiving MTX alone or in combination with other disease-modifying anti-rheumatic drugs (DMARDs). Most of the subjects from whom synovial specimens were obtained were also older women with chronic rheumatoid factor-positive RA.
###end p 47
###begin p 48
###xml 10 18 <span type="species:ncbi:9606">patients</span>
The 23 RA patients enrolled in a clinical trial comparing MTX plus infliximab with MTX alone had disease of shorter duration (median 4.4, infliximab + MTX: 3.0 and MTX: 5.7 years).
###end p 48
###begin title 49
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 63 65 63 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
RA patients have a reduced peripheral blood pre-switch IgD+CD27+ memory B cell population
###end title 49
###begin p 50
###xml 177 182 177 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a, b</xref>
###xml 271 273 271 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 305 306 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 310 312 310 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 443 445 439 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 682 683 672 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 687 689 677 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 738 740 728 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1030 1032 1016 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1102 1104 1084 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1184 1186 1160 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1226 1227 1202 1203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1231 1233 1207 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1471 1473 1443 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
###xml 955 963 <span type="species:ncbi:9606">patients</span>
###xml 1513 1521 <span type="species:ncbi:9606">patients</span>
###xml 1782 1790 <span type="species:ncbi:9606">patients</span>
The frequencies of B cell subsets defined by the expression of IgD and CD27 in the peripheral blood of patients with long-standing RA were compared with healthy donors (Figures 1a, b). One striking finding was that the subjects with long-standing RA had a significantly (P = 0.0031) lower frequency of IgD+CD27+ pre-switch memory B cells than the healthy donors (median RA 10.4 +/- 1.3% vs control 15.1 +/- 1.1%). This significant difference (P = 0.0036) was maintained when analysing the absolute number of pre-switch memory B cells (median RA: 13.8 +/- 4.7 cells/mul vs control: 21.3 +/- 3.9 cells/mul). On the other hand, the frequency - but not the absolute numbers - of the IgD-CD27+ post-switch memory population was significantly (P = 0.0101) increased in subjects with long-standing RA when compared with the control individuals (median RA 19.6 +/- 2.9% vs control 13.2 +/- 1.0%). Interestingly, no significant difference could be seen between RA patients and controls in the frequency or absolute number of the total CD27+ memory B cell pool (median RA 31.3 +/- 3.8% vs control 30.3 +/- 1.6%, P = 0.6258; median RA 41.0 +/- 11.3 cells/mul vs control: 44.6 +/- 5.0 cells/mul, P = 0.7022). Finally, the frequency of IgD+CD27- naive B cell population in the peripheral blood of subjects with long-standing RA was comparable with the healthy donors (median RA 57.3 +/- 4.1% vs control 65.6 +/- 1.7%). However, the absolute number of naive B cells was significantly (P = 0.0231) lower in the long-standing RA patients when compared with the control individuals (median RA: 61.4 +/- 28.6 cells/mul vs control: 100.5 +/- 10.7 cells/mul). These differences could not be the result of B cell lymphopenia, because the absolute number of the total B cell pool in the long-standing RA patients was comparable to the healthy donors (median RA 151.0 +/- 35.8 cells/mul vs control: 148.5 +/- 20.0 cells/mul).
###end p 50
###begin p 51
###xml 122 126 122 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 179 181 179 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 349 353 349 353 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 517 519 517 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 544 546 544 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 550 552 550 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 575 577 575 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 581 583 581 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 801 803 801 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 757 765 <span type="species:ncbi:9606">patients</span>
RA patients, irrespective of disease duration show marked shifts in the frequency of the peripheral blood B cell subsets. (a) Dot-plots of IgD versus CD27 of peripheral blood CD19+ B cells from representative healthy control and a long-standing rheumatoid arthritis (RA) patients illustrating the differences in the frequency of each B cell subset. (b) Box-plots representing the 10th, 25th, 50th (median), 75th and 90th percentiles of the frequencies of the total B cells (as a percentage of lymphocytes), total CD27+ memory B cells, naive IgD+ CD27- B cells, pre-switch IgD+ CD27+ memory B cells and post-switch IgD-CD27+ memory B cells (each as a percentage of B cells) in the peripheral blood of healthy donors (n = 40, white bars) and long-standing RA patients (n = 33, grey bars). *Significant (P < 0.01) difference from control donors.
###end p 51
###begin p 52
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 733 735 729 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 841 843 831 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 887 889 877 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1025 1027 1015 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1263 1265 1249 1251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1309 1311 1295 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
###xml 1050 1057 <span type="species:ncbi:9606">patient</span>
###xml 1334 1341 <span type="species:ncbi:9606">patient</span>
In order to assess whether disease duration had an influence on the B cell subset disparities between RA patients and healthy individuals, the frequencies of the different B cell subpopulations in the RA patients with long-standing disease (natural history patients, median disease duration 13 years) were compared with the baseline values of another group of patients with shorter disease duration (median disease duration 4.4 years) who had enrolled in a clinical trial examining the impact of MTX versus that of the combination of MTX and infliximab (Table 1). Both groups had comparable frequencies and absolute numbers of pre-switch memory B cells (median shorter disease: 10.2 +/- 1.5% vs long-standing disease: 10.4 +/- 1.3%, P = 0.8156; median shorter disease 14.4 +/- 2.9 cells/mul vs long-standing disease: 13.8 +/- 4.7 cells/mul, P = 0.4003), each of which was significantly (P < 0.03) lower than that found in the healthy controls. Notably, however, the frequency of post-switch memory B cells was significantly (P = 0.0025) lower in the patient group with shorter disease duration when compared with the long-standing group (median shorter disease: 9.7 +/- 2.9% vs longer standing disease: 19.6 +/- 2.9%). Furthermore, the frequency of the total CD27+ memory B cell population was significantly (P = 0.0184) lower in the patient group with shorter disease duration when compared with the long-standing group (median shorter disease: 19.1 +/- 3.2% vs longer standing disease: 31.3 +/- 3.8%).
###end p 52
###begin title 53
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 44 46 44 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Reduced peripheral blood pre-switch IgD+CD27+ memory B cell population is not the result of CD27 shedding
###end title 53
###begin p 54
###xml 119 120 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 124 126 124 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 164 166 164 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 302 303 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 307 309 307 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 428 429 428 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 470 471 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 475 477 475 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 484 485 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 489 491 489 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 613 614 613 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 618 620 618 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 651 653 651 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H </sub>
###xml 800 801 800 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 805 807 805 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 833 835 833 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 875 876 875 876 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 880 882 880 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 944 946 944 946 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H </sub>
###xml 970 972 970 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 996 997 996 997 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1001 1003 1001 1003 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1017 1018 1017 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1061 1062 1061 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1066 1068 1066 1068 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 1085 1093 <span type="species:ncbi:9606">patients</span>
Shedding of surface CD27 from peripheral blood pre-switch memory B cells could account for the reduced frequency of IgD+CD27+ B cells in RA patients. Moreover, CD27- memory B cells have been recently reported in healthy individuals [14,16] and in SLE patients [15]. Therefore, to verify whether the IgD+CD27- B cells in RA patients were actually naive, single-cell PCR analysis of immunoglobulin heavy chain variable region (IgVH) genes from sorted peripheral blood, IgD+CD27+ and IgD+CD27- RA B cells, was carried out to determine the frequency of somatic mutations in those subsets. As expected, most of the IgD+CD27- B cells expressed unmutated IgVH genes (76%) and those that were mutated contained few mutations. Both the frequency of mutated Ig sequences and the mutational frequency in the IgD+CD27- subset was significantly (P < 0.05) lower when compared with the IgD+CD27+ subset. Moreover, the mean number of somatic mutations per IgVH gene was significantly (P < 0.05) lower in the IgD+CD27- subset (Table 2). Thus, there was no evidence that the IgD+CD27- population of RA patients contained a subgroup of pre-switch memory B cells that failed to express CD27.
###end p 54
###begin p 55
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Mutational frequencies of B cell subsets in peripheral blood from patients with rheumatoid arthritis
###end p 55
###begin p 56
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 26 28 26 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 52 54 52 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 57 59 57 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 76 78 76 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 81 83 81 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 87 89 87 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
a Significant difference (P < 0.05) between the CD19+ IgD+ CD27 and the CD19+ IgD+ CD27+ subsets.
###end p 56
###begin p 57
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
To confirm that CD27 shedding from the surface of memory B cells was unlikely to be responsible for the reduction of the pre-switch memory B cell population in the peripheral blood of RA patients, the levels of soluble CD27 in the serum of RA patients and control individuals were determined by ELISA. As other studies have previously reported [31], no differences could be detected between healthy donors and RA patients (data not shown).
###end p 57
###begin title 58
###xml 4 6 4 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
CD27+ memory B cells accumulate in the synovial membrane of RA patients
###end title 58
###begin p 59
###xml 88 89 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 651 653 647 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 670 672 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 694 695 690 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 698 700 694 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 732 733 728 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 736 738 732 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 414 421 <span type="species:ncbi:9606">patient</span>
###xml 482 489 <span type="species:ncbi:9606">patient</span>
It is known that the rheumatoid synovial membrane is infiltrated by B and plasma cells [3,6]. In order to determine the nature of the B cell subsets that comprise the synovial B cell population in long-standing RA, lymphocytes isolated from the synovial membrane and from peripheral blood of RA patients with long-standing disease were phenotyped by flow cytometry. As depicted in Figure 2a for one representative patient, the majority of the synovial B cells express CD27. In this patient cohort the rheumatoid synovial membrane had significantly more CD27-expressing B cells than the peripheral blood (61.4 +/- 10.4% vs 25.1 +/- 15.6% respectively; P < 0.0001; Figure 2b). Both pre-switch IgD+IgM+ memory cells and post-switch IgD-IgM- memory cells were found in the synovial tissue (data not shown).
###end p 59
###begin p 60
###xml 4 6 4 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 81 85 81 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 230 232 230 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 322 326 322 326 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 479 481 479 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 143 150 <span type="species:ncbi:9606">patient</span>
CD27+ memory B cells tend to accumulate in the synovial membrane of RA patients. (a) Histogram from a representative rheumatoid arthritis (RA) patient showing the difference in CD27 expression in peripheral blood and synovial CD19+ B cells. Dashed line shows staining with the isotype control and the solid line for CD27. (b) Box-plots representing the 10th, 25th, 50th (median), 75th and 90th percentiles of the frequency of CD27 expression by peripheral blood and synovial CD19+ B cells in long-standing RA (n = 10).
###end p 60
###begin title 61
RA peripheral blood and synovial memory B cells express abnormal chemokine receptor patterns
###end title 61
###begin p 62
###xml 208 210 208 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 353 355 353 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 558 560 558 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 612 613 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 776 778 776 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
Chemokine receptor expression by RA B cells can be indicative of their preferential capability for homing into the inflamed tissues. To assess whether the expression of chemokine receptors by RA synovial CD27+ memory B cells could contribute to the skewed distribution of the different B cell subsets in the RA synovial membrane, the frequencies of CD27+ memory B cells expressing specific chemokine receptors was also determined. Notably, expression of CXCR1, CXCR2, CXCR4 and CCR2 was significantly elevated in synovial compared with blood memory B cells (P < 0.00001) of either controls or RA patients (Table 3). Moreover, RA blood B cells manifested significantly enhanced expression of CXCR1, CXCR2 and CCR2 and decreased expression of CXCR4 compared with control blood (P < 0.02).
###end p 62
###begin p 63
###xml 37 39 37 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 43 45 43 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Chemokine receptor expression by CD19+ CD27+ memory B cells from peripheral blood of healthy donors and RA patients and in RA synovium
###end p 63
###begin p 64
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 36 38 36 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
a indicates significant difference (P < 0.02) between controls and patients with rheumatoid arthritis (RA);
###end p 64
###begin p 65
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 36 38 36 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
b indicates significant difference (P < 0.00001) between RA blood and synovium.
###end p 65
###begin p 66
Data are means +/- standard error of the mean.
###end p 66
###begin title 67
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 50 52 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Anti-TNF therapy increases the pre-switch IgD+CD27+ memory B cell population
###end title 67
###begin p 68
###xml 18 19 18 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 104 106 104 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 382 384 382 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
As shown in Table 4, the group of patients receiving infliximab plus MTX therapy exhibited significant (P < 0.05) improvement of several laboratory and clinical parameters, including disease activity score, rheumatoid factor titres, ESR and the number of swollen and tender joints. By contrast, after the sixth treatment, the group receiving MTX monotherapy manifested significant (P < 0.05) improvement only in disease activity score and in the number of tender joints.
###end p 68
###begin p 69
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Laboratory and clinical parameters of the patients undergoing MTX or MTX plus infliximab therapy at baseline (first visit) and after six treatments (seventh visit)
###end p 69
###begin p 70
Data are means +/- standard error of the mean.
###end p 70
###begin p 71
###xml 2 4 2 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
* P < 0.05 between first and seventh visit.
###end p 71
###begin p 72
CRP = C-reactive protein; DAS = disease activity score; ESR = erythrocyte sedimentation rate; MTX = methotrexate; RF = rheumatoid factor; SJC = swollen joints count; TJC = tender joints count.
###end p 72
###begin p 73
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 347 348 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 352 354 352 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 372 373 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 377 379 377 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 412 413 412 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 417 419 417 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 944 946 932 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 280 288 <span type="species:ncbi:9606">patients</span>
###xml 494 502 <span type="species:ncbi:9606">patients</span>
###xml 736 744 <span type="species:ncbi:9606">patients</span>
###xml 966 974 <span type="species:ncbi:9606">patients</span>
In order to determine whether anti-TNF therapy had an effect on the distribution of the different peripheral blood B cell subsets in RA, the frequencies of those subsets were calculated after six administrations of study drug (Figure 3). At the time of the first visit all the RA patients in both treatment groups had comparable frequencies of IgD+CD27- naive B cells, IgD+CD27+ pre-switch memory B cells and IgD-CD27+ post-switch B cells. Before any of the therapies had been initiated all RA patients and healthy controls had a comparable frequency of naive B cells (median controls: 65.6 +/- 1.7% vs infliximab + MTX: 76.5 +/- 4.4%; MTX: 81.4 +/- 6.7%). Similarly, the frequency of the post-switch memory B cell population in all RA patients before treatment was comparable to healthy donors (median control: 13.6 +/- 1.0% vs infliximab + MTX: 9.7 +/- 2.6%; MTX: 8.7 +/- 3.4%), whereas the pre-switch memory B cell subset was significantly (P < 0.03) lower in RA patients than in the control individuals (median control: 15.1 +/- 1.1% vs infliximab + MTX: 11.2 +/- 1.5%; MTX: 5.4 +/- 3.1%).
###end p 73
###begin p 74
###xml 160 164 160 164 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 267 269 267 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 273 275 273 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 453 457 453 457 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 560 562 560 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 566 568 566 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 743 747 743 747 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 850 852 850 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 856 858 856 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1034 1038 1034 1038 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 1148 1150 1148 1150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1329 1331 1329 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
###xml 931 939 <span type="species:ncbi:9606">patients</span>
###xml 1211 1219 <span type="species:ncbi:9606">patients</span>
TNF blockade induces an increase in the frequency of peripheral blood total memory and pre-switch memory B cells, while reducing the circulating naive B cells. (a) Box plots representing the 10th, 25th, 50th (median), 75th and 90th percentiles of the frequency of IgD+ CD27- naive B cells at the time of the 1st and 7th visits for the patients in the infliximab plus methotrexate (MTX) group (n = 15, grey bars) and MTX monotherapy (n = 8, white bars). (b) Box plots representing the 10th, 25th, 50th (median), 75th and 90th percentiles of the frequency of IgD+ CD27+ pre-switch memory B cells at the time of the 1st and 7th visits for the patients in the infliximab plus MTX group (n = 15, grey bars) and MTX monotherapy (n = 8, white bars). (c) Box plots representing the 10th, 25th, 50th (median), 75th and 90th percentiles of the frequency of IgD- CD27+ post-switch memory B cells at the time of the 1st and 7th visits for the patients in the infliximab plus MTX group (n = 15, grey bars) and MTX monotherapy (n = 8, white bars). (d) Box plots representing the 10th, 25th, 50th (median), 75th and 90th percentiles of the frequency of total CD27+ memory B cells at the time of the 1st and 7th visits for the patients in the infliximab plus MTX group (n = 15, grey bars) and MTX monotherapy (n = 8, white bars). * Significant (P < 0.01) difference from 1st visit.
###end p 74
###begin p 75
###xml 122 124 122 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
When compared with the baseline values from the first visit, the RA patients receiving infliximab plus MTX significantly (P < 0.01) increased the frequency of total and pre-switch peripheral memory B cells after the sixth round of treatment (median baseline 11.2 +/- 1.5% vs after treatment 14.7 +/- 1.8%) However, no changes could be observed in the patients receiving MTX alone (median baseline 5.4 +/- 3.1% vs after treatment 5.9 +/- 2.4%).
###end p 75
###begin p 76
###xml 161 168 <span type="species:ncbi:9606">patient</span>
In order to determine whether the changes observed after TNF-blockade exclusively involved B cells, the frequencies of CD4 and CD8 T cells were analysed in both patient groups. However, no changes were observed between visits in either treatment group (data not shown).
###end p 76
###begin title 77
Discussion
###end title 77
###begin p 78
###xml 73 75 73 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 443 444 443 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 448 450 448 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 781 782 781 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 786 788 786 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1126 1128 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
###xml 1108 1116 <span type="species:ncbi:9606">patients</span>
###xml 1232 1240 <span type="species:ncbi:9606">patients</span>
Abnormal distributions of peripheral B cell subsets, particularly of CD27+ memory B cells, have been reported in several autoimmune diseases including RA [15-18,20,21]. However, in RA there is no consensus about the nature of the abnormalities, because some reports note an increase and others no change in peripheral memory B cells [19-21]. In the present study, we report that RA patients have a lower frequency of circulating pre-switch IgD+CD27+ memory B cells when compared with healthy individuals. Importantly, memory B cells accumulate in the synovial membrane of subjects with RA, suggesting that accumulation of pre-switch memory B cells within inflamed tissue may contribute to a decrease in this B cell subset in the blood. It should be pointed out that post-switch IgD-CD27+ memory B cells are also enriched in the rheumatoid synovium, although these cells are not decreased in the blood in early RA. This discrepancy may be explained by the more complex homeostasis of post-switch memory B cells. Although these cells accumulate in the synovium, they are also generated in increased numbers in patients with RA [19]. As a result, post-switch memory B cells accumulate not only in the synovium but also in the blood of patients with long-standing RA.
###end p 78
###begin p 79
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 93 95 93 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 114 115 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 119 121 119 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 213 215 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 358 359 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 363 365 363 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 500 501 500 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 505 507 505 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 841 843 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 980 982 980 982 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1020 1022 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1023 1025 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1065 1066 1065 1066 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1070 1072 1070 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1102 1103 1102 1103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1107 1109 1107 1109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1165 1167 1165 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1323 1324 1323 1324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1328 1330 1328 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1529 1530 1529 1530 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1534 1536 1534 1536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1893 1894 1893 1894 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1898 1900 1898 1900 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 2228 2230 2228 2230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 2406 2407 2406 2407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 2411 2413 2411 2413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 775 783 <span type="species:ncbi:9606">patients</span>
###xml 864 872 <span type="species:ncbi:9606">patients</span>
###xml 1238 1246 <span type="species:ncbi:9606">patients</span>
###xml 1363 1371 <span type="species:ncbi:9606">patients</span>
###xml 1578 1586 <span type="species:ncbi:9606">patients</span>
###xml 1749 1757 <span type="species:ncbi:9606">patients</span>
###xml 2169 2176 <span type="species:ncbi:9606">patient</span>
The human memory B cell population is heterogeneous, comprising mutated pre-switched IgD+CD27+ and post-switch IgD-CD27+ B cells [13,32], that develop with age [33]. It is widely accepted that post-switch IgD-CD27+ memory B cells are post-germinal centre highly mutated memory B cells [11,13,32,34]. However, the function and the origin of the pre-switch IgD+CD27+ subpopulation is still a matter of controversy. Despite some characterisation [35], it has not been clearly established whether the IgD+CD27+ memory population only participates in T cell-independent immune responses, because this population expresses heavily mutated Ig genes [32]. The role of this population in autoimmune diseases has been stressed by the finding that in the peripheral blood of SLE and SS patients the pre-switch memory B cell subset is markedly reduced [18,36]. However, in RA patients with long-standing disease, previously published data suggested that there might be an accumulation of CD27+ memory cells in the peripheral blood [20,21], and especially of the post-switch IgD-CD27+ memory subset, whereas the IgD+CD27+ subset was reported to be comparable to healthy donors [20]. We were unable to confirm these findings. Instead, we observed that patients with RA manifested a marked reduction in the peripheral blood pre-switch IgD+CD27+ subset. At baseline the group of patients engaged in the clinical trial and those with shorter disease duration had similarly lower frequencies and absolute numbers of peripheral blood pre-switch IgD+CD27+ memory B cells compared with the group of patients with long-standing disease, so this abnormality would seem to be an integral feature of RA, independent of disease duration. Preliminary assessment of a group of patients with very early RA, who had disease duration of less than six weeks and had received no DMARD therapy, also indicated a decrease in IgD+CD27+ pre-switch memory B cells and is consistent with the conclusion that this abnormality in memory B cell homeostasis is characteristic of RA independent of disease duration and DMARD therapy (R Moura and JE Fonseca, unpublished data). Notably, in none of the analysed RA patient groups did we observe an increase in the total CD27+ memory B cells when compared with control subjects. Nevertheless, with long-standing disease in both the National Institutes of Health and Japanese cohorts, the post-switch IgD-CD27+ population was increased. This is likely to be related to the increased production of post-switch memory B cells owing to persistent immunological stimulation that is sufficient to overcompensate for the enhanced sequestration of these cells in the synovium.
###end p 79
###begin p 80
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 364 366 364 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
###xml 613 621 <span type="species:ncbi:9606">patients</span>
The disparities between our data and the results previously reported [19-21] may be explained by a number of factors, including disease duration, cohort size and therapy. Importantly, most studies did not analyse patients in terms of disease duration, which as we report here can clearly affect memory B cell subset distribution. It is notable that when total CD27+ memory B cells were analysed in patients receiving only MTX therapy, a remarkably broad range of distributions was noted, with some patients with very high and others with low frequencies [19]. Finally, some studies did not separately analyse the patients on TNF-blockers, which can alter peripheral blood memory subset distribution as found here and reported previously [19].
###end p 80
###begin p 81
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 330 331 330 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 335 337 335 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 560 562 560 562 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H </sub>
###xml 578 579 578 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 583 585 583 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 778 779 778 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 783 785 783 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 652 660 <span type="species:ncbi:9606">patients</span>
Elevated concentrations of matrix metalloproteinases, with the capacity to cleave molecules of the TNF-family from the cell surface [37], have been reported in RA synovial fluid [38], and soluble CD27 is increased in the synovial fluid but not in the serum of RA patients [31]. Therefore, it was possible that the reduction of IgD+CD27+ B cells in RA patients could be the result of proteolytic cleavage of CD27 (a TNF-receptor family member [39]) from the cell surface of pre-switch memory B cells. However, the negligible number of somatic mutations in the VH genes of the IgD+CD27- subset and the comparable serological levels of soluble CD27 in RA patients and healthy individuals discounted the possibility that CD27 had been cleaved from the cell surface of pre-switch IgD+CD27+ memory B cells, therefore giving them a false-naive phenotype.
###end p 81
###begin p 82
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 514 515 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 519 521 519 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 719 721 719 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1241 1243 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1500 1502 1500 1502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1735 1737 1735 1737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1844 1846 1844 1846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1996 1998 1996 1998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 2036 2038 2036 2038 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 2119 2121 2119 2121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 2410 2411 2410 2411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 2506 2508 2506 2508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 472 480 <span type="species:ncbi:9606">patients</span>
###xml 1910 1914 <span type="species:ncbi:10090">mice</span>
###xml 2009 2014 <span type="species:ncbi:9606">human</span>
Chemokine receptor imbalances have been reported in several autoimmune diseases [21,40-43]. Additionally, several studies have provided strong evidence that in RA synovium and synovial fluid, monocytes/macrophages, synovial fibroblasts, FDC and mast cells have an increased expression of either chemokines or their receptors responsible for B and T cell recruitment [4,44-48]. Together with an accumulation of both subsets of memory B cells in the synovial membrane of RA patients with reduced peripheral blood IgD+CD27+ B cells, we have also observed significant shifts in the expression of several chemokine receptors in the RA peripheral blood B cell subsets and in the synovial memory B cells: the frequency of CD27+ memory B cells expressing the pro-inflammatory CXCR1, CXCR2 and CCR2 chemokine receptors [49,50] was elevated in both peripheral blood and synovium; and contrary to RA peripheral blood, the large majority of synovial membrane memory B cells expressed CXCR4. The high frequency of RA peripheral blood and synovial membrane memory B cells expressing pro-inflammatory chemokine receptors, such as the IL8-receptors CXCR1 and CXCR2, or CCR2 (a negative modulator of cytoskeleton rearrangement and immature B cell migration [51]), stresses the potential role of interactions of memory B cells with other effector cells of the immune system that could contribute to the perpetuation of chronic synovitis. An important, and novel, finding was the abnormally increased frequency of CXCR4+ memory B cells in the RA synovium. CXCR4 is the receptor for the homeostatic and pro-inflammatory chemokine CXCL12 and is expressed by mature naive B cells when they recirculate through germinal centres of secondary lymphoid organs [52]. CXCR4 expression is essential for correct formation of the dark and light zones of the germinal centre [53]. Moreover, CXCR4 is involved in plasma cell function, because mice lacking CXCR4 expression present major abnormalities in plasma cell homeostasis [54], whereas human peripheral blood CD27+ memory B cells increase CXCR4 expression upon differentiation into plasma cells [55]. The importance of CXCR4 expression in synovial membrane inflammation has been emphasised by the inhibition of collagen-induced arthritis by the CXCR4 antagonist T140, and by the finding of elevated CXCR4 gene expression in RA synovial biopsies with follicular-like lymphoid structures [4]. Therefore, our data are consistent with the possibility that in RA elevated numbers of CXCR4+ memory B cells may be recruited into the synovial membrane where they accumulate, and might be involved in seeding follicular-like structures and/or differentiating into autoantibody-secreting plasma cells, thus perpetuating the chronic synovitis.
###end p 82
###begin p 83
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 547 548 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1001 1003 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 2197 2199 2189 2191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 2227 2229 2219 2221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 2890 2891 2878 2879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 730 738 <span type="species:ncbi:9606">patients</span>
###xml 1282 1290 <span type="species:ncbi:9606">patients</span>
###xml 1603 1611 <span type="species:ncbi:9606">patients</span>
###xml 1743 1751 <span type="species:ncbi:9606">patients</span>
###xml 1899 1907 <span type="species:ncbi:9606">patients</span>
###xml 2336 2344 <span type="species:ncbi:9606">patients</span>
###xml 2620 2628 <span type="species:ncbi:9606">patients</span>
Anti-TNF therapy in RA has been linked to a reduction of B cells expressing the early activation marker CD23 in the peripheral blood [56]. Neutralising TNF in RA diminishes the production of pro-inflammatory cytokines in the joints, lowers the levels of circulating IL1, IL6 and acute-phase proteins [22,25], and decreases the serological levels of ICAM-1, ICAM-3, VCAM-1, VEGF and E-selectin [57,58]. In the synovium, infliximab induces a major reduction of sublining T cells, B cells and macrophages [59], decreases ectopic lymphoid neogenesis [5], and lowers the expression of IL8 and MCP-1/CCL2 [60]. A major finding in the present study was the normalisation of the peripheral blood pre-switch memory B cell population in RA patients who received anti-TNF therapy, which was accompanied by a significant amelioration of several clinical parameters. This recovery of circulating pre-switch memory B cells after infliximab treatment contrasts with the findings in a recent report using etanercept [19]. By blocking TNF and LTalpha simultaneously with etanercept, the possible effects of LTalpha on B cell homeostasis and GC formation make it difficult to identify the individual contribution of TNF-blockade on the B cell compartment in RA. As a result of treating a group of RA patients with infliximab, (that specifically blocks TNF) we have found an increase in circulating pre-switch memory B cells. It is difficult to be certain whether the increase in pre-switch memory B cells specifically related to an improvement in disease activity or specifically the blockade of TNF. In this regard, the patients who received only MTX therapy exhibited some improvement in clinical disease activity, but it was not as profound as that noted in patients treated with MTX and infliximab. Therefore, it is uncertain whether the lack of significant change in circulating pre-switch memory B cells in the patients receiving MTX resulted from a failure to block TNF completely or from an incomplete clinical response. The effect of TNF blockade, however, did appear to be specific for pre-switch memory B cells. Although, previous studies reported a transient increase in T cell counts after four weeks [61] and after repeated doses [62] of anti-TNF therapy, we could not detect any significant changes in any of the T cell populations in the patients treated with the combination of infliximab and MTX. Therefore, these results suggest that neutralising TNF alone might block the migration of memory B cells into the synovium without a persistent effect on T cell trafficking, which support recent findings showing that in RA patients with disease remission after anti-TNF therapy (using either specific TNF blockers or simultaneous blockade of TNF and LTalpha) the number and the density of B cells in the synovial membrane and the frequency of ectopic germinal centres significantly decreased [5].
###end p 83
###begin title 84
Conclusions
###end title 84
###begin p 85
###xml 97 105 <span type="species:ncbi:9606">patients</span>
In summary, the present findings indicate that the reduction of circulating memory B cells in RA patients, particularly the pre-switch memory subset, might be linked to their accumulation in the inflamed rheumatoid synovium under the influence of TNF.
###end p 85
###begin title 86
Abbreviations
###end title 86
###begin p 87
###xml 373 374 373 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 27 33 <span type="species:ncbi:9913">bovine</span>
###xml 253 257 <span type="species:ncbi:9913">calf</span>
APC: allophycocyanin; BSA: bovine serum albumin; CRP: C-reactive protein; DMARD: disease-modifying anti-rheumatic drugs; DMEM: Dulbecco's Modified Eagle's Medium; ELISA: enzyme-linked immunosorbent assay; ESR: erythrocyte sedimentation rate; FCS: fetal calf serum; FDC: follicular dendritic cell; FITC: fluorescein isothiocyanate; ICAM: intercellular adhesion molecule; IgVH: immunoglobulin heavy chain variable region; IL: interleukin; LT: lymphotoxin; MAb: monoclonal antibodies; MTX: methotrexate; PBMC: peripheral blood mononuclear cells; PBS: phosphate-buffered saline; PCR: polymerase chain reaction; PE: phycoerythrin; PerCpCy5.5: peridinin-chlorophyll-protein Cy5.5; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SS: Sjogren's syndrome; TNF: tumour necrosis factor; VCAM: vascular cell adhesion molecule; VEGF: vascular endothelial growth factor.
###end p 87
###begin title 88
Competing interests
###end title 88
###begin p 89
The authors declare that they have no competing interests.
###end p 89
###begin title 90
Authors' contributions
###end title 90
###begin p 91
###xml 244 251 <span type="species:ncbi:9606">patient</span>
MMS-C collected data, designed experiments, carried out statistical analysis and wrote the manuscript. VM carried out the clinical study and collected data. RG-M designed and carried out the clinical study. RF, KT, TN, MW, MB and TAF collected patient data. PEL designed and coordinated the study and wrote the manuscript.
###end p 91
###begin title 92
Acknowledgements
###end title 92
###begin p 93
This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases Intramural Research Program. MMSC was supported by the Marie Curie Intra-European Fellowship, LIF-025885 and EULAR Young Investigator Award.
###end p 93
###begin article-title 94
Pathogenesis of rheumatoid arthritis: how early is early?
###end article-title 94
###begin article-title 95
The role of B cells in the pathogenesis of rheumatoid arthritis
###end article-title 95
###begin article-title 96
Histopathology and molecular pathology of synovial B-lymphocytes in rheumatoid arthritis
###end article-title 96
###begin article-title 97
Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis
###end article-title 97
###begin article-title 98
Clinical significance of synovial lymphoid neogenesis and its reversal after anti-TNF-{alpha} therapy in rheumatoid arthritis
###end article-title 98
###begin article-title 99
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis
###end article-title 99
###begin article-title 100
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis
###end article-title 100
###begin article-title 101
Ectopic germinal center formation in rheumatoid synovitis
###end article-title 101
###begin article-title 102
B lymphocyte depletion in rheumatoid arthritis: targeting of CD20
###end article-title 102
###begin article-title 103
IgM and IgG but not cytokine secretion is restricted to the CD27+ B lymphocyte subset
###end article-title 103
###begin article-title 104
###xml 23 28 <span type="species:ncbi:9606">human</span>
Functional analysis of human memory B-cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM
###end article-title 104
###begin article-title 105
###xml 116 121 <span type="species:ncbi:9606">human</span>
IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells
###end article-title 105
###begin article-title 106
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells
###end article-title 106
###begin article-title 107
A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation
###end article-title 107
###begin article-title 108
Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95
###end article-title 108
###begin article-title 109
A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus
###end article-title 109
###begin article-title 110
###xml 57 65 <span type="species:ncbi:9606">children</span>
Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus
###end article-title 110
###begin article-title 111
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome
###end article-title 111
###begin article-title 112
Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks
###end article-title 112
###begin article-title 113
Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses
###end article-title 113
###begin article-title 114
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus
###end article-title 114
###begin article-title 115
Development of anti-TNF therapy for rheumatoid arthritis
###end article-title 115
###begin article-title 116
###xml 21 26 <span type="species:ncbi:9606">human</span>
TNFalpha blockade in human diseases: An overview of efficacy and safety
###end article-title 116
###begin article-title 117
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
###end article-title 117
###begin article-title 118
How does infliximab work in rheumatoid arthritis?
###end article-title 118
###begin article-title 119
Adhesion molecules in autoimmune disease
###end article-title 119
###begin article-title 120
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Increased lymphangiogenesis in joints of mice with inflammatory arthritis
###end article-title 120
###begin article-title 121
The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis
###end article-title 121
###begin article-title 122
###xml 117 125 <span type="species:ncbi:9606">patients</span>
Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis
###end article-title 122
###begin article-title 123
###xml 24 29 <span type="species:ncbi:9606">human</span>
Characterization of the human Ig heavy chain antigen binding complementarity determining region 3 using a newly developed software algorithm, JOINSOLVER
###end article-title 123
###begin article-title 124
Expression of the activation antigen CD27 in rheumatoid arthritis
###end article-title 124
###begin article-title 125
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human IgM+CD27+ B cells: memory B cells or "memory" B cells?
###end article-title 125
###begin article-title 126
###xml 97 103 <span type="species:ncbi:9606">humans</span>
CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(-) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances
###end article-title 126
###begin article-title 127
###xml 20 25 <span type="species:ncbi:9606">human</span>
Germinal centers in human lymph nodes contain reactivated memory B cells
###end article-title 127
###begin article-title 128
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human blood IgM 'memory' B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire
###end article-title 128
###begin article-title 129
###xml 59 67 <span type="species:ncbi:9606">patients</span>
A new CD21low B cell population in the peripheral blood of patients with SLE
###end article-title 129
###begin article-title 130
Processing of tumour necrosis factor-alpha precursor by metalloproteinases
###end article-title 130
###begin article-title 131
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis
###end article-title 131
###begin article-title 132
CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein
###end article-title 132
###begin article-title 133
Surface expression of CC- and CXC-chemokine receptors on leucocyte subsets in inflammatory joint diseases
###end article-title 133
###begin article-title 134
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjogren's syndrome
###end article-title 134
###begin article-title 135
Homing chemokines in rheumatoid arthritis
###end article-title 135
###begin article-title 136
Chemokine receptors in the rheumatoid synovium: upregulation of CXCR5
###end article-title 136
###begin article-title 137
Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis
###end article-title 137
###begin article-title 138
Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis
###end article-title 138
###begin article-title 139
###xml 125 133 <span type="species:ncbi:9606">patients</span>
High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis
###end article-title 139
###begin article-title 140
###xml 161 169 <span type="species:ncbi:9606">patients</span>
Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients
###end article-title 140
###begin article-title 141
Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts
###end article-title 141
###begin article-title 142
Lymphocyte traffic control by chemokines
###end article-title 142
###begin article-title 143
Chemokines: a new classification system and their role in immunity
###end article-title 143
###begin article-title 144
Expression of the chemokine receptor CCR2 on immature B cells negatively regulates their cytoskeletal rearrangement and migration
###end article-title 144
###begin article-title 145
Chemokines in the systemic organization of immunity
###end article-title 145
###begin article-title 146
Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5
###end article-title 146
###begin article-title 147
A coordinated change in chemokine responsiveness guides plasma cell movements
###end article-title 147
###begin article-title 148
Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells
###end article-title 148
###begin article-title 149
###xml 42 50 <span type="species:ncbi:9606">patients</span>
B cell activation in rheumatoid arthritis patients under infliximab treatment
###end article-title 149
###begin article-title 150
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis
###end article-title 150
###begin article-title 151
###xml 155 163 <span type="species:ncbi:9606">patients</span>
Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab
###end article-title 151
###begin article-title 152
Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue
###end article-title 152
###begin article-title 153
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis
###end article-title 153
###begin article-title 154
###xml 127 135 <span type="species:ncbi:9606">patients</span>
Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy
###end article-title 154
###begin article-title 155
###xml 51 59 <span type="species:ncbi:9606">patients</span>
In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2
###end article-title 155

